candesartan has been researched along with Coronary Heart Disease in 9 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan therapy significantly reduced inflammation and increased adiponectin levels and improved insulin sensitivity in hypertensive patients." | 5.12 | Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. ( Chung, WJ; Han, SH; Koh, KK; Lee, Y; Quon, MJ; Shin, EK, 2006) |
| "The calcium antagonist felodipine, the lipid-peroxidation inhibitor H290/51, and the angiotensin II type 1 (AT1)-receptor antagonist candesartan all exert beneficial effects on myocardial ischemia/reperfusion injury." | 3.70 | Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs. ( Rydén, L; Shimizu, M; Sjöquist, PO; Wang, QD, 1999) |
| "Candesartan treatment reduced primary end point risk (5." | 2.71 | Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. ( Kondo, J; Kono, T; Kosaka, T; Matsui, H; Morishima, I; Mukawa, H; Murohara, T; Numaguchi, Y; Okumura, K; Sone, T; Tsuboi, H; Uesugi, M; Yoshida, T, 2003) |
| "Losartan is a non-peptidic inhibitor of AT1 receptors." | 2.41 | Angiotensin II AT(1) receptor antagonists and platelet activation. ( Casado, S; Gómez, J; Jiménez, A; Lopez-Bloya, A; López-Farré, A; Montón, M; Núñez, A; Rico, L; Sánchez de Miguel, L, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rickenbacher, P | 1 |
| Owen, OG | 1 |
| Tiefenbacher, CP | 1 |
| Friedrich, S | 1 |
| Bleeke, T | 1 |
| Vahl, C | 1 |
| Chen, X | 1 |
| Niroomand, F | 1 |
| Kondo, J | 1 |
| Sone, T | 1 |
| Tsuboi, H | 1 |
| Mukawa, H | 1 |
| Morishima, I | 1 |
| Uesugi, M | 1 |
| Kono, T | 1 |
| Kosaka, T | 1 |
| Yoshida, T | 1 |
| Numaguchi, Y | 1 |
| Matsui, H | 1 |
| Murohara, T | 1 |
| Okumura, K | 1 |
| Coca, SG | 1 |
| Buller, GK | 1 |
| Koh, KK | 1 |
| Quon, MJ | 1 |
| Han, SH | 1 |
| Chung, WJ | 1 |
| Lee, Y | 1 |
| Shin, EK | 1 |
| Cheung, BM | 1 |
| Shimizu, M | 1 |
| Wang, QD | 1 |
| Sjöquist, PO | 1 |
| Rydén, L | 1 |
| López-Farré, A | 1 |
| Sánchez de Miguel, L | 1 |
| Montón, M | 1 |
| Jiménez, A | 1 |
| Lopez-Bloya, A | 1 |
| Gómez, J | 1 |
| Núñez, A | 1 |
| Rico, L | 1 |
| Casado, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation[NCT00139386] | Phase 4 | 1,119 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for candesartan and Coronary Heart Disease
| Article | Year |
|---|---|
[Heart failure with "mid-range" ejection fraction: a new clinical entity?]
Topics: Aged; Aminobutyrates; Benzimidazoles; Biomarkers; Biphenyl Compounds; Comorbidity; Coronary Disease; | 2018 |
Therapeutic potential of angiotensin receptor blockers in hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2006 |
Angiotensin II AT(1) receptor antagonists and platelet activation.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin Receptor Antagonists | 2001 |
2 trials available for candesartan and Coronary Heart Disease
| Article | Year |
|---|---|
Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease.
Topics: Aged; Angina Pectoris; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Coronar | 2003 |
Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Benzimidazoles; Biph | 2006 |
4 other studies available for candesartan and Coronary Heart Disease
| Article | Year |
|---|---|
EUROPA shows role for ACE inhibition in low-risk CHD.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compound | 2003 |
ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles.
Topics: Acetylcholine; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibito | 2004 |
Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compo | 2004 |
Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs.
Topics: Anesthesia; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Antioxidants; Benzim | 1999 |